Preconditioning of adipose tissue-derived mesenchymal stem cells with deferoxamine increases the production of pro-angiogenic, neuroprotective and anti-inflammatory factors: Potential application in the treatment of diabetic neuropathy
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Diabetic neuropathy (DN) is one of the most frequent and troublesome complications of diabetes mellitus. Evidence from diabetic animal models and diabetic patients suggests that reduced availability of neuroprotective and pro-angiogenic factors in the nerves in combination with a chronic pro-inflammatory microenvironment and high level of oxidative stress, contribute to the pathogenesis of DN. Mesenchymal stem cells (MSCs) are of great interest as therapeutic agents for regenerative purposes, since they can secrete a broad range of cytoprotective and anti-inflammatory factors. Therefore, the use of the MSC secretome may represent a promising approach for DN treatment. Recent data indicate that the paracrine potential of MSCs could be boosted by preconditioning these cells with an environmental or pharmacological stimulus, enhancing their therapeutic efficacy. In the present study, we observed that the preconditioning of human adipose tissue-derived MSCs (AD-MSCs) with 150μM or 400μM of the iron chelator deferoxamine (DFX) for 48 hours, increased the abundance of the hypoxia inducible factor 1 alpha (HIF-1α) in a concentration dependent manner, without affecting MSC morphology and survival. Activation of HIF-1α led to the up-regulation of the mRNA levels of pro-angiogenic factors like vascular endothelial growth factor alpha and angiopoietin 1. Furthermore this preconditioning increased the expression of potent neuroprotective factors, including nerve growth factor, glial cell-derived neurotrophic factor and neurotrophin-3, and cytokines with anti-inflammatory activity like IL4 and IL5. Additionally, we observed that these molecules, which could also be used as therapeutics, were also increased in the secretome of MSCs preconditioned with DFX compared to the secretome obtained from non-preconditioned cells. Moreover, DFX preconditioning significantly increased the total antioxidant capacity of the MSC secretome and they showed neuroprotective effects when evaluated in an in vitro model of DN. Altogether, our findings suggest that DFX preconditioning of AD-MSCs improves their therapeutic potential and should be considered as a potential strategy for the generation of new alternatives for DN treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
Global estimates of diabetes prevalence for 2013 and projections for 2035
Guariguata, L., Whiting, D. R., Hambleton, I., Beagley, J., Linnenkamp, U., & Shaw, J. E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.11.002 · Cited by 4,642
Mesenchymal stem cells as trophic mediators
Caplan, A. I., & Dennis, J. E. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20886 · Cited by 2,992
Caplan, A. I., & Correa, D. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2011.06.008 · Cited by 1,682
Mesenchymal Stem/Stromal Cells (MSCs): Role as Guardians of Inflammation
Prockop, D. J., & Youn Oh, J. (2012) · Molecular Therapy · doi:10.1038/mt.2011.211 · Cited by 816
Yamakawa, M., Liu, L. X., Date, T., Belanger, A. J., Vincent, K. A., Akita, G. Y., Kuriyama, T., Cheng, S. H., Gregory, R. J., & Jiang, C. (2003) · Circulation Research · doi:10.1161/01.res.0000093984.48643.d7 · Cited by 327
Coppey, L. J., Gellett, J. S., Davidson, E. P., Dunlap, J. A., Lund, D. D., & Yorek, M. A. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1927 · Cited by 300
Diabetic peripheral neuropathic pain: clinical and quality-of-life issues
Argoff, C. E., Cole, B. E., Fishbain, D. A., & Irving, G. A. (2006) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)61474-2 · Cited by 256
Can VEGF reverse diabetic neuropathy in human subjects?
Veves, A., & King, G. L. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13038 · Cited by 88
Coppey, L. J., Gellett, J. S., Davidson, E. P., & Yorek, M. A. (2003) · Free Radical Research · doi:10.1080/1071576021000028442 · Cited by 82
Cited by
Baldari, S., Di Rocco, G., Piccoli, M., Pozzobon, M., Muraca, M., & Toietta, G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102087 · Cited by 279
Li, M., Jiang, Y., Hou, Q., Zhao, Y., Zhong, L., & Fu, X. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02822-2 · Cited by 119
Cell secretome: basic insights and therapeutic opportunities for CNS disorders
Pinho, A. G., Cibrão, J. R., Silva, N. A., Monteiro, S., & Salgado, A. J. (2020) · Pharmaceuticals · doi:10.3390/ph13020031 · Cited by 94
“Improvements in the secretome of ASCs was also observed increasing the secretion of proangiogenic, neuroprotective, and anti-inflammatory molecules and increasing the antioxidant capacity of their secretome when preconditioned with deferoxamine [56].”
BackgroundMoeinabadi-Bidgoli, K., Babajani, A., Yazdanpanah, G., Farhadihosseinabadi, B., Jamshidi, E., Bahrami, S., & Niknejad, H. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112026 · Cited by 70
Metadata
- Authors
- Oses, C., Olivares, B., Ezquer, M., Acosta, C., Bosch, P., Donoso, M., Léniz, P., & Ezquer, F.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-05-19
- Volume
- 12
- Issue
- 5
- Pages
- e0178011
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2619089544
- Cited by
- 137
- References
- 10
- FWCI
- 6.96
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preconditioning of adipose tissue-derived mesenchymal stem cells with deferoxamine increases the production of pro-angiogenic, neuroprotective and anti-inflammatory factors: Potential application in the treatment of diabetic neuropathy. https://app.cochat.ai/papers/10.1371/journal.pone.0178011
- The paper
- Oses, C., Olivares, B., Ezquer, M., Acosta, C., Bosch, P., Donoso, M., Léniz, P., & Ezquer, F. (2017). Preconditioning of adipose tissue-derived mesenchymal stem cells with deferoxamine increases the production of pro-angiogenic, neuroprotective and anti-inflammatory factors: Potential application in the treatment of diabetic neuropathy. PLOS ONE. https://doi.org/10.1371/journal.pone.0178011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.